Opendata, web and dolomites

CYPNASH SIGNED

Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CYPNASH project word cloud

Explore the words cloud of the CYPNASH project. It provides you a very rough idea of what is the project "CYPNASH" about.

scaffolds    cellular    optimize    sub    vivo    biological    animal    decade    actions    platform    previously    pursuing    damage    pursued    treating    dmpk    structurally    unexplored    inhibit    inhibition    industry    delivering    liver    non    basis    form    mitochondrial    disease    family    permeability    cyclophilin    cyclophilins    erc    efficacy    drug    selectivity    asset    vitro    follow    undertaken    innovative    compelling    alcoholic    optimisation    discovery    licensing    discovered    prevalent    preclinical    inhibitors    assembles    approved    maximize    binding    team    biophysical    assembling    pore    pk    treatments    computational    data    protein    small    absence    population    partnering    steatohepatitis    trials    unmet    designed    molecules    cells    fibrosis    models    chronic    therapy    business    modulation    selective    healthcare    programs    macrocyclic    company    triple    candidate    pharmacological    agents    peptidic    mechanism    valuable    scientists    poc    ebdd    pharmaceutical    stg    medical    consultation    validate    nash       basic    physical    pocket    orally    clinical    mode    suitable    bioavailable    compound    executives    transition   

Project "CYPNASH" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF EDINBURGH 

Organization address
address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL
website: www.ed.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) coordinator 150˙000.00

Map

 Project objective

Non-alcoholic steatohepatitis (NASH) is an increasingly prevalent chronic liver disease (3-4% of the US population) for which there is currently no approved drug therapy. In the absence of innovative treatments healthcare costs associated with this disease are set to triple over the next decade. To address this unmet medical need, the pharmaceutical industry is currently pursuing a range of liver fibrosis drug discovery programs based on different mode of actions. A compelling mechanism for treating liver damage is pharmacological modulation of the mitochondrial permeability transition pore in liver cells via inhibition of the protein cyclophilin D. However existing cyclophilin inhibitors based on peptidic macrocyclic scaffolds are challenging to optimize into sub-type selective orally bioavailable agents suitable for clinical trials of liver fibrosis.

As part of basic research activities undertaken during ERC StG EBDD to validate a computational-biophysical drug discovery platform, we have discovered a structurally novel family of small molecules that inhibit cyclophilins by targeting a previously unexplored binding pocket. The objective of this POC is to identify a lead compound in this family with potential for development towards a NASH clinical candidate. Such a candidate will form the basis of follow-on lead optimisation programs pursued via partnering or out-licensing with a pharmaceutical partner. The activities of this POC will focus on assembling a data package of in vitro DMPK, in vivo PK, in vitro sub-type selectivity and in vitro and in vivo efficacy measurements in relevant cellular and animal models of liver fibrosis. This POC has been designed in consultation with a major pharmaceutical company and assembles a team of physical and biological scientists and business development executives to maximize the likelihood of delivering a valuable preclinical NASH asset.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYPNASH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYPNASH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

MERIR (2019)

Methane related iron reduction processes in sediments: Hidden couplings and their significance for carbon and iron cycles

Read More